This site is intended only for Australian Healthcare Professionals
Choose your country
By clicking a link below you are choosing to leave the BioMarin Australia website; the country chosen is responsible for the content on that website.

Phenylketonuria (PKU)
Resource Library

 

 

Patient Videos

PKU management in adults returning to treatment – Monique’s story

Monique (26 yrs) shares her story of getting back on track after going off diet for a number of years

Click to watch

PKU management in adults returning to treatment – Con’s story

Con (51 yrs) shares his regrets about being off diet for 37 years

Click to watch

PKU management in adulthood – Bianca’s story

Bianca (29 yrs) shares her experience of managing PKU with a strict diet

Click to watch

PKU management in pregnancy – Katy’s story

Katy (41 yrs) shares her challenges of managing PKU during pregnancy

Click to watch

PKU management in adolescence – Tom & Josh’s story

Josh & Tom (13 & 11 yrs) and Mum, talk about family life with PKU and their initial experiences with KUVAN®

Click to watch

Related Resources

KUVAN® Resource Library

KUVAN® Video Library

Contact Us

Please contact us for more information.

Products available in Australia

BRINEURA® (cerliponase alfa)

BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

KUVAN® (sapropterin dihydrochloride)

KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.

NAGLAZYME® (galsulfase (rch))

NAGLAZYME® is indicated as long term enzyme replacement therapy in patients with Mucopolysaccharidosis VI (MPS VI, Nacetylgalactosamine 4- sulfatase deficiency, Maroteaux-Lamy syndrome).

VIMIZIM® (elosulfase alfa (rch))

VIMIZIM® is indicated for the treatment of MPS IVA (Mucopolysaccharidosis type IVA, morquio A syndrome).

VOXZOGO® (vosoritide)

VOXZOGO® is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.